Companies › Ultragenyx Pharmaceutical
7 active drug programs in 12 registered trials: 6 Phase 3, 3 Phase 1, 3 Phase 2; Metabolic and endocrine, Other, Neurology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| setrusumab Sclerostin inhibitor | SOST | Phase 3 | Osteogenesis Imperfecta | Jan 2027 |
| Triheptanoin (UX007, Dojolvi) Odd-chain triglyceride providing propionyl-CoA for anaplerotic replenishment of TCA cycle | – | Phase 3 | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD); Pyruvate Dehydrogenase Complex Deficiency | Aug 2027 |
| DTX301 (avalotcagene ontaparvovec) AAV8-mediated gene transfer encoding functional OTC | OTC | Phase 3 | OTC Deficiency | Sep 2027 |
| GTX-102 (apazunersen) Antisense oligonucleotide targeting UBE3A | UBE3A | Phase 3 | Angelman Syndrome | – |
| UX111 Self-complementary adeno-associated virus serotype 9 (scAAV9) carrying the human SGSH gene | SGSH | Phase 2 | MPS IIIA | Mar 2029 |
| UX016 | – | Phase 1 | GNE Myopathy | Dec 2028 |
| UX701 (rivunatpagene miziparvovec) Nonreplicating recombinant gene transfer vector delivering functional ATP7B gene | ATP7B | Phase 1 | Wilson Disease | Mar 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06617429 | GTX-102 (apazunersen) | Phase 3 | Angelman Syndrome | Other | Jul 2026 |
| NCT06415344 | GTX-102 (apazunersen) | Phase 3 | Angelman Syndrome | Other | Oct 2026 |
| NCT07157254 | GTX-102 (apazunersen) | Phase 2 | Angelman Syndrome | Other | Oct 2026 |
| NCT06636071 | setrusumab | Phase 3 | Osteogenesis Imperfecta | Other | Jan 2027 |
| NCT05768854 | setrusumab | Phase 3 | Osteogenesis Imperfecta | Other | Apr 2027 |
| NCT05125809 | setrusumab | Phase 2 | Osteogenesis Imperfecta | Other | Apr 2027 |
| NCT05933200 | Triheptanoin (UX007, Dojolvi) | Phase 3 | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | Metabolic and endocrine | Aug 2027 |
| NCT05345171 | DTX301 (avalotcagene ontaparvovec) | Phase 3 | OTC Deficiency | Metabolic and endocrine | Sep 2027 |
| NCT07511556 | UX016 | Phase 1 | GNE Myopathy | Neurology | Dec 2028 |
| NCT06340685 | Triheptanoin (UX007, Dojolvi) | Phase 1 | Pyruvate Dehydrogenase Complex Deficiency | Metabolic and endocrine | Dec 2028 |
| NCT04884815 | UX701 (rivunatpagene miziparvovec) | Phase 1 | Wilson Disease | Metabolic and endocrine | Mar 2029 |
| NCT02716246 | UX111 | Phase 2 | MPS IIIA | Metabolic and endocrine | Mar 2029 |
Cash and short-term investments of $266m on 2026-09-30; operating cash outflow about $452m a year; runway about 7 months at that burn, to May 2027; 3 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Vivet Therapeutics SAS Orphalan Prime Medicine CAMP4 Therapeutics Arcturus Therapeutics iECURE Amgen GC Biopharma MavriX Bio Ionis Pharmaceuticals
BioMarin Pharmaceutical Beijing QL Biopharmaceutical Gan & Lee Pharmaceuticals. Biomea Fusion CSPC Ouyi Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.